公开(公告)号：US09890145B2

公开(公告)日：2018-02-13

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D405/14 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48 ,  C07D403/04 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107 ,  C07D495/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.